Mubadala Healthcare, a leading UAE health care provider is contributing to a British-based clinical trial involving diabetic patients and their battle to overcome the effects of COVID-19. The Gulf Nation health system is contributing to the funding of this clinical trial investigating an immune-inhibiting drug approved by the UK’s Medicines and Healthcare Products Agency (MHRA). Known as the Arcadia trial, the investigational therapy is based on preclinical research of a specific enzyme that “could help diabetes patients with COVID-19 by dampening the overactive response of the immune system that is typically acute in those patients with raised blood glucose levels,” reported Mubadala Healthcare. With a start date of Sept. 29 the trial is for hospitalized patients diagnosed with mild to moderate COVID-19 symptoms.
Within the UAE over 1 million people struggle with diabetes. With the onset of COVID-19, this group is even at higher risk to health problems. Reported Abdulla Abdul Aziz Al Shansi, head of Mubadala Healthcare. Al Shansi suggested that the UAE government is investing considerable sums to protect the population from COVID-19.
This study was made possible by a collaborative contribution of funding and resources involving not only Mubadala Healthcare, Excalibur Medicines Ltd. (EML), several private partners and the UK government. The actual drug agent was developed by AstraZeneca for another purpose but research led by St. George Street Capital Ltd. (SGS) found the treatment evidenced promise if repurposed for diabetes research.
If this study is successful, the compound could possibly be prescribed by doctors and physicians for people with diabetes who evidence early symptoms associated with COVID-19.
About Mubadala Healthcare
Mubadala Healthcare seeks to develop a world-class, commercially sustainable private healthcare sector in the UAE. Via a range of partnerships with local and international medical institutions they have developed a network of specialized facilities seeking to enhance regional healthcare capacity while addressing UAE’s most pressing healthcare needs, while reducing the need for patients to travel overseas for complex care.